Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07220577 · ClinicalTrials.gov registry record · Phase 2
Phase 2a Study to Assess the Efficacy,Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis
A Phase 2 study of Atopic Dermatitis, sponsored by Novartis Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 84
- Enrollment target
- 20
- Study locations
NCT07220577: Recruiting Phase 2 study of Atopic Dermatitis, sponsored by Novartis Pharmaceuticals.
NCT07220577 is a Phase 2 study of Atopic Dermatitis that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 84 participants, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (86% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07220577, a Phase 2 study of Atopic Dermatitis, is actively recruiting participants, sponsored by Novartis Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 84 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this Ph2a study is to evaluate the preliminary efficacy, safety and tolerability of GIA632 when administered to adult participants with moderate to severe atopic dermatitis (AD).
Primary Outcome
To assess the efficacy of GIA632 compared to placebo at week 16
Conditions Studied
Interventions
- OTHER Placebo
- DRUG GIA632
Study Locations (20)
Other
- Novartis Investigative Site - Pleven
- Novartis Investigative Site - Sofia
- Novartis Investigative Site - Sofia
- Novartis Investigative Site - Prague
- Novartis Investigative Site - Antony
- Novartis Investigative Site - Dijon
- Novartis Investigative Site - Martigues
- Novartis Investigative Site - Nice
- Novartis Investigative Site - Berlin
- Novartis Investigative Site - Hamburg
- Novartis Investigative Site - Mainz
- Novartis Investigative Site - Kuala Lumpur
California
- Ctr for Dermatology Clinical Res - Fremont
Maryland
- Aesthetics Skin Care Dermatologic Surgery - Rockville
New Jersey
- Care Access Hoboken - Hoboken
Ontario
- Novartis Investigative Site - Toronto
Quebec
- Novartis Investigative Site - Québec
Poruba
- Novartis Investigative Site - Ostrava
Perak
- Novartis Investigative Site - Ipoh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2025-11-10 |
| Est. Completion | 2027-09-06 |
| Phase | Phase 2 |
What NCT07220577 shows while recruiting
NCT07220577 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 84 participants, a relatively small participant target, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (86% lower).
The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07220577 names 20 study sites across 9 states, led by Other, California, Maryland.
Frequently Asked Questions
What is clinical trial NCT07220577 about?
NCT07220577 is a clinical study titled "Phase 2a Study to Assess the Efficacy,Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis". The main purpose of this Ph2a study is to evaluate the preliminary efficacy, safety and tolerability of GIA632 when administered to adult participants with moderate to severe atopic dermatitis (AD).
What is the current status of trial NCT07220577?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 84 participants. The study started on 2025-11-10. Estimated completion is 2027-09-06.
What conditions does trial NCT07220577 study?
This clinical trial studies the following conditions: Atopic Dermatitis.
What interventions are being tested in trial NCT07220577?
The interventions under investigation include: Placebo (OTHER), GIA632 (DRUG).
Who is sponsoring clinical trial NCT07220577?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07220577 being conducted?
This trial has 20 study locations across California, Maryland, New Jersey, Ontario, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07220577's enrollment target sits among peer trials
84 96th of 150 higher than 55 of 150 other Atopic Dermatitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atopic Dermatitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Cardamom and Topical Roseomonas in Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
A Study Evaluating TRIV-509 in Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02391519 · 84 participants
Effects of High Altitude on AMPK Activation
- NCT03838536 · 84 participants · NA
Synergistic Activity of Human Milk Nutrients and Infant Cognition
- NCT03884075 · 84 participants · Phase 2
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
- NCT03894917 · 84 participants
Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI